Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: Preliminary results of a single-arm phase II clinical trial Meeting Abstract
| Authors: | Yang, C.; Shih, J.; Chao, T.; Tsai, C.; Yu, C.; Yang, P.; Streit, M.; Shahidi, M.; Miller, V. A. |
| Abstract Title: | Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: Preliminary results of a single-arm phase II clinical trial |
| Meeting Title: | 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 26 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2008 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2008-05-20 |
| Start Page: | 430s |
| Language: | English |
| ACCESSION: | WOS:000208457402876 |
| DOI: | 10.1200/jco.2008.26.15_suppl.8026 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 8026 -- Source: Wos |
